Compare ACADIA Pharmaceuticals Inc. (ACAD) vs Motorola Solutions Inc (MSI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ACADIA Pharmaceuticals Inc. vs Motorola Solutions Inc — how do they compare? ACADIA Pharmaceuticals Inc. trades at $29.55 (market cap $5.07B), while Motorola Solutions Inc trades at $465.61 (market cap $77.26B). The key difference: Motorola Solutions Inc is far larger — about 15.2× ACADIA Pharmaceuticals Inc.'s market cap, and Motorola Solutions Inc pays a 1.04% dividend while ACADIA Pharmaceuticals Inc. pays none. Which is the better fit depends on your goals.
| ACAD | MSI | |
|---|---|---|
Market Cap | $5.07B | $77.26B |
Sector | Health | Technology |
52-Week High | $29.41 | $490.30 |
52-Week Low | $20.06 | $363.83 |
Enterprise Value | $4.19B | $86.17B |
Dividend Yield | — | 1.04% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACADIA Pharmaceuticals (ACAD) trades at $29.39, up 0.62% on the day, with strong earnings momentum after Q2 2026 results beat expectations. The stock shows bullish technical signals from moving averages, though oscillators suggest potential overbought conditions. Revenue growth has been robust, rising from $517M in 2022 to $1.07B in 2025, with net income turning positive and margins expanding significantly. Recent news highlights FDA Fast Track designation for remlifanserin and raised 2026 revenue guidance.
Outlook remains positive driven by product sales growth and pipeline advancements, but risks include clinical trial outcomes and competitive pressures. Analyst consensus is strongly bullish with a $33.89 price target, indicating ~15% upside. Investment appeal hinges on execution of commercial strategy and successful drug development.
Motorola Solutions (MSI) trades at $461.98, down 1.19% today but has demonstrated strong momentum with three consecutive quarterly earnings beats and a 23.5% gain over three months. The company reported record Q2 2026 results with 13% revenue growth and raised full-year guidance, supported by a record $15.6 billion backlog. Technical indicators show a bullish trend with the stock near its pivot point of $463, while valuation metrics remain elevated with a P/E of 36.79.
The outlook remains positive given strong demand in public safety communications and software services, with analyst consensus pointing to 15% upside to the $533.80 price target. Key risks include execution challenges to meet elevated expectations and the premium valuation requiring sustained high growth. The combination of operational strength and bullish sentiment supports a constructive view for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Read more on ACAD →About Motorola Solutions Inc
Motorola Solutions, Inc. is a data communications and telecommunications equipment provider. The Company develops data capture, wireless, infrastructure, bar code scanning, two-way radios, and wireless broadband networks. Motorola also produces public safety and government products, voice and data communications products and systems, and wireless LAN securities.
Read more on MSI →
